Table 2 Baseline demographic data and clinical characteristics of the study population
From: Flow cytometric analysis of platelets type 2 diabetes mellitus reveals ‘angry’ platelets
Variable | Controls (n = 30) | Diabetics without CVD (n = 30) | Diabetics with CVD (n = 30) |
|---|---|---|---|
Age, years | 25 ± 9.64 | 53 ± 13.7 | 61 ± 9.4 |
Males, n (%) | 6 (20) | 11 (37) | 20 (67) |
Females, n (%) | 24 (80) | 19 (63) | 10 (33) |
Hypertension, n (%) | 17 (57) | 26 (87) | |
Diabetic treatment | |||
Insulin, n (%) | 5 (17) | 3 (10) | |
Oral agents only, n (%) | 16 (53) | 12 (40) | |
Oral and insulin, n (%) | 9 (30) | 15 (50) | |
HBA1c %a | 9.0 ± 2.6 | 8.5 ± 1.7 | |
Cardiovascular complications | |||
Previous MI, n (%) | 19 (63) | ||
PAD, n (%) | 2 (7) | ||
CABG, n (%) | 9 (30) | ||
Essential medication | |||
ACEI, n (%) | 10 (33) | 20 (67) | |
Ca-antagonist, n (%) | 8 (27) | 3 (10) | |
Β-blocker, n (%) | 3 (10) | 11 (37) | |
Nitrates, n (%) | 1 (3) | 14 (47) | |
Statins, n (%) | 10 (33) | 25 (83) | |
Disprin, n (%) | 6 (20) | 20 (67) | |
Warfarin, n (%) | 2 (7) | 5 (17) | |